CLS B — Clinical Laserthermia Systems AB Share News
0.000.00%
Last trade - 00:00- SEK90.69m
- SEK83.48m
- SEK17.49m
Brief: CLS's Acting CEO Dan J. Mogren To Go On Planned Sick Leave
Brief: CLS And Skåne University Hospital Enter Clinical Trial Agreement
Brief: CLS Files Application For Approval Of Tranberg To U.S. FDA
Brief: Clinical Laserthermia Systems Q3 EBIT Loss Widens To SEK 11.9 Mln
Brief: CLS Q2 Pretax Loss Widens To SEK 23.1 Million
Brief: CLS, Toronto General Hospital Resume Clinical Trial For Prostate Cancer As Co Receives Approval For Updated Sterilization Process By Health Canada
Brief: CLS To Use SEK 15 Million Of Loan Commitment
Brief: Clinical Laserthermia Systems Q1 Pre-tax Loss Narrows To SEK 9.5 Mln
Brief: CLS Announces Oversubscribed Rights Issue
Brief: CLS Recalls Its Sterile Disposable Instruments After New Information
Brief: Clinical Laserthermia Systems Gets FDA Approval For Next Generation TRANBERG Laser Applicator
Brief: Clinical Laserthermia Systems AB To Utilize Loan Promise Of Sek 15 Million
Brief: Clinical Laserthermia Systems AB - Gets New Order
Brief: Clinical Laserthermia Systems Gets New Patent In EU
Brief: Clinical Laserthermia Systems Gets Order From Immunophotonics
Brief: Clinical Laserthermia Systems AB - Q3 Operating Loss Sek 8.3 Million
Brief: CLS Appoints Dan Mogren As Acting CEO
Brief: Clinical Laserthermia Gets CPT Reimbursement Code Approval
Brief: Clinical Laserthermia Systems Q2 Pretax Loss Widens To SEK 12.9 Mln